Skip to content
Inciteful Med

Understanding Systemic Primary Carnitine Deficiency (SPCD): The Basics

Last updated:

Systemic Primary Carnitine Deficiency (SPCD) is a rare but highly treatable genetic disorder where cells cannot absorb carnitine, preventing the body from using fat for energy. With early diagnosis and lifelong L-carnitine supplementation, patients can live normal, healthy lives.

Key Takeaways

  • • SPCD is a genetic metabolic condition caused by a mutation in the SLC22A5 gene, which impairs the OCTN2 carnitine transporter.
  • • Early diagnosis, most often through newborn screening, allows doctors to begin treatment before organ damage occurs.
  • • The condition is highly treatable with lifelong oral L-carnitine supplementation.
  • • Without treatment, SPCD can cause severe complications like cardiomyopathy, heart failure, and severe hypoglycemia.
  • • Patients who consistently adhere to their L-carnitine treatment regimen generally have a normal life expectancy and quality of life.

Receiving a diagnosis of Systemic Primary Carnitine Deficiency (SPCD)—also called Carnitine Transporter Deficiency—often happens suddenly through a newborn screening report. It is natural to feel overwhelmed or fearful when told your child has a rare metabolic condition [1]. However, SPCD is unique among metabolic disorders because it is highly treatable. With early and consistent management, the life-threatening risks associated with the condition are preventable, and individuals can lead healthy, active lives [2][3].

What is SPCD?

SPCD is a genetic condition that changes how the body handles carnitine, a natural substance found in meat and dairy and also produced by the body [4]. Your body needs carnitine to move certain fats into the mitochondria (the “power plants” of your cells) so they can be burned for energy [4][5].

In a person with SPCD, the “doorway” that lets carnitine into the cells is broken [6]. This doorway is a protein called OCTN2, which is created by the SLC22A5 gene [7][8]. Because the carnitine cannot get into the cells where it is needed, it is instead lost in the urine, leaving the body with dangerously low levels [7][9]. Without enough carnitine, the body cannot effectively use fat for fuel, which can lead to energy shortages in critical organs like the heart and liver [6][10].

To understand how SPCD is diagnosed, visit the Diagnosis & Biology page.

How Common is It?

SPCD is rare, which is why many general practitioners may not be deeply familiar with it.

  • Global Prevalence: It is estimated to affect approximately 1 in 35,000 to 1 in 50,000 people worldwide [11].
  • Carrier Frequency: About 1 in every 95 people is a carrier (meaning they have one mutated gene but do not have the condition themselves) [11].
  • Regional Differences: It is much more common in certain areas due to “founder effects.” For example, in the Faroe Islands, the prevalence is as high as 1 in 300 [12]. It is also more frequently diagnosed in parts of China and Japan [13][14].

Why Early Detection Matters

Before newborn screening was common, SPCD was often only discovered after a person became very ill. Today, catching it early allows doctors to start treatment before any damage occurs. Learn what to look for on the Symptoms & Warning Signs page.

Prognosis With Treatment

When L-carnitine supplementation is started early and continued for life, the prognosis is excellent [2].

  • Heart Health: Treatment can prevent or even reverse cardiomyopathy (an enlarged or weakened heart) [15][16].
  • Prevention: It prevents “metabolic crises,” such as sudden drops in blood sugar (hypoglycemia) during illness [1].
  • Life Expectancy: Patients who stay on their Treatment Strategy generally have a normal life expectancy and quality of life [2][17].

Risks Without Treatment

If left untreated, the severe lack of carnitine can lead to sudden, life-threatening complications, including heart failure, dangerous heart rhythms (arrhythmias), or coma [18][19]. This is why staying consistent with supplementation is the most important part of managing the condition [1].

SPCD vs. Secondary Deficiency

You may hear the term “secondary carnitine deficiency.” This is different from SPCD. In secondary deficiency, the carnitine transporter (the “doorway”) works fine, but carnitine is being used up or lost because of a different medical problem or medication [20][21]. In SPCD, the problem is the genetic “blueprint” for the transporter itself [22]. Precise genetic testing is the “gold standard” used to confirm that a patient has SPCD rather than a temporary or secondary low level [23][24].

Frequently Asked Questions

What is systemic primary carnitine deficiency (SPCD)?
SPCD is a rare genetic condition where the body's cells cannot properly absorb carnitine due to a broken transport protein. Without carnitine, the body cannot convert fats into energy, leading to dangerous shortages in critical organs like the heart and liver.
How is SPCD treated?
The primary treatment for SPCD is lifelong L-carnitine supplementation. When started early and taken consistently, it corrects the deficiency, prevents severe complications, and allows individuals to live healthy, active lives.
What happens if SPCD is left untreated?
Without treatment, a severe lack of carnitine can lead to sudden, life-threatening complications. These include dangerous drops in blood sugar during illness, heart rhythm problems, an enlarged heart, and even coma.
What is the difference between primary and secondary carnitine deficiency?
In primary carnitine deficiency, the genetic doorway that transports carnitine into cells is broken. Secondary deficiency means this transporter works normally, but carnitine levels are low due to a different medical problem or medication.
Can a child with SPCD have a normal life expectancy?
Yes, the prognosis is excellent for individuals with SPCD who stick to their daily treatment. As long as they consistently take their L-carnitine supplements, patients generally enjoy a normal life expectancy and good quality of life.

Questions for Your Doctor

  • • What was the specific free carnitine (C0) level on the newborn screen, and what is the target range we are aiming for with treatment?
  • • Can you explain my (or my child’s) specific genetic mutations and whether they are typically associated with symptoms or an asymptomatic course?
  • • How often should we schedule heart-related tests, such as EKGs or echocardiograms, to monitor cardiac health?
  • • What is the emergency plan if a stomach virus or illness prevents the intake of oral carnitine supplements?
  • • Given how rare this is, how many other patients with SPCD do you currently manage?

Questions for You

  • • How has my (or my child’s) energy level or muscle strength been lately? Have I noticed any unusual fatigue or weakness?
  • • Am I able to consistently manage the schedule for carnitine supplementation, or do I need a better system to ensure no doses are missed?
  • • What concerns or fears do I have about this diagnosis that I haven't yet shared with my medical team?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Newborn screening for primary carnitine deficiency in Quanzhou, China.

    Lin W, Wang K, Zheng Z, et al.

    Clinica chimica acta; international journal of clinical chemistry 2021; (512()):166-171 doi:10.1016/j.cca.2020.11.005.

    PMID: 33181153
  2. 2

    Patients with primary carnitine deficiency treated with L-carnitine are alive and doing well-A 10-year follow-up in the Faroe Islands.

    Abrahamsen RK, Lund AM, Rasmussen J

    JIMD reports 2023; (64(6)):453-459 doi:10.1002/jmd2.12383.

    PMID: 37927485
  3. 3

    Primary systemic carnitine deficiency: a Turkish case with a novel homozygous SLC22A5 mutation and 14 years follow-up.

    Yilmaz BS, Kor D, Mungan NO, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2015; (28(9-10)):1179-81.

    PMID: 26030785
  4. 4

    Carnitine Inborn Errors of Metabolism.

    Almannai M, Alfadhel M, El-Hattab AW

    Molecules (Basel, Switzerland) 2019; (24(18)) doi:10.3390/molecules24183251.

    PMID: 31500110
  5. 5

    Acylcarnitines in Cancer Metabolism: Mechanistic Insights and Stratification Potential.

    Lee HP, Oh J, Lee N, et al.

    Cancers 2026; (18(4)) doi:10.3390/cancers18040713.

    PMID: 41749966
  6. 6

    Structural basis of sodium ion-dependent carnitine transport by OCTN2.

    Davies JS, Zeng YC, Briot C, et al.

    Nature communications 2025; (17(1)):181 doi:10.1038/s41467-025-66867-6.

    PMID: 41318751
  7. 7

    Maternal Primary Carnitine Deficiency and a Novel Solute Carrier Family 22 Member 5 (SLC22A5) Mutation.

    Jakoby M, Jaju A, Marsh A, Wilber A

    Journal of investigative medicine high impact case reports 2021; (9()):23247096211019543 doi:10.1177/23247096211019543.

    PMID: 34032155
  8. 8

    A Rare Treatable Cause of Cardiomyopathy: Primary Carnitine Deficiency.

    Basan H, Azak E, Çetin İİ, et al.

    Molecular syndromology 2024; (15(2)):156-160 doi:10.1159/000534932.

    PMID: 38585546
  9. 9

    Involvement of impaired carnitine-induced fatty acid oxidation in experimental and human diabetic kidney disease.

    Ito S, Taguchi K, Kodama G, et al.

    JCI insight 2025; (10(13)).

    PMID: 40402578
  10. 10

    Carnitine traffic and human fertility.

    Mazza T, Scalise M, Console L, et al.

    Biochemical pharmacology 2024; (230(Pt 1)):116565 doi:10.1016/j.bcp.2024.116565.

    PMID: 39368751
  11. 11

    The global prevalence and genetic spectrum of primary carnitine deficiency.

    Sun L, Yao K, Wu HJ

    BMC genomic data 2025; (26(1)):44 doi:10.1186/s12863-025-01336-z.

    PMID: 40624458
  12. 12

    Residual OCTN2 transporter activity, carnitine levels and symptoms correlate in patients with primary carnitine deficiency.

    Rasmussen J, Lund AM, Risom L, et al.

    Molecular genetics and metabolism reports 2014; (1()):241-248 doi:10.1016/j.ymgmr.2014.04.008.

    PMID: 27896095
  13. 13

    Newborn Screening and Genetic Analysis Identify Six Novel Genetic Variants for Primary Carnitine Deficiency in Ningbo Area, China.

    Yang X, Li Q, Wang F, et al.

    Frontiers in genetics 2021; (12()):686137 doi:10.3389/fgene.2021.686137.

    PMID: 34249102
  14. 14

    [Mutational analysis of SLC22A5 gene in eight patients with systemic primary carnitine deficiency].

    Lin Y, Lin W, Yu K, et al.

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2017; (34(1)):35-39 doi:10.3760/cma.j.issn.1003-9406.2017.01.008.

    PMID: 28186590
  15. 15

    Dilated Cardiomyopathy as the Only Clinical Manifestation of Carnitine Transporter Deficiency.

    Papadopoulou-Legbelou K, Gogou M, Dokousli V, et al.

    Indian journal of pediatrics 2017; (84(3)):231-233 doi:10.1007/s12098-016-2250-8.

    PMID: 27807682
  16. 16

    Primary carnitine deficiency - diagnosis after heart transplantation: better late than never!

    Grünert SC, Tucci S, Schumann A, et al.

    Orphanet journal of rare diseases 2020; (15(1)):87 doi:10.1186/s13023-020-01371-2.

    PMID: 32276632
  17. 17

    [Clinical and genetic characteristics of primary carnitine deficiency identified by neonatal screening].

    Li X, Zhu X, Jia C, et al.

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2019; (36(12)):1167-1170 doi:10.3760/cma.j.issn.1003-9406.2019.12.004.

    PMID: 31813139
  18. 18

    Systemic primary carnitine deficiency induces severe arrhythmia due to shortening of QT interval.

    Lodewyckx P, Issa J, Gaschignard M, et al.

    Molecular genetics and metabolism 2023; (140(4)):107733 doi:10.1016/j.ymgme.2023.107733.

    PMID: 37979236
  19. 19

    Systemic Primary Carnitine Deficiency Presenting With Substantia Nigra and Basal Ganglia Injury: A Case Report.

    Saito T, Soma K, Kashisaka M, et al.

    JIMD reports 2025; (66(3)):e70014 doi:10.1002/jmd2.70014.

    PMID: 40191062
  20. 20

    Slc22a5 haploinsufficiency does not aggravate the phenotype of the long-chain acyl-CoA dehydrogenase KO mouse.

    Ranea-Robles P, Yu C, van Vlies N, et al.

    Journal of inherited metabolic disease 2020; (43(3)):486-495 doi:10.1002/jimd.12204.

    PMID: 31845336
  21. 21

    Primary carnitine deficiency with severe acute hepatitis following rotavirus gastroenteritis.

    Ishige M, Fuchigami T, Furukawa M, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2019; (25(11)):913-916 doi:10.1016/j.jiac.2019.04.020.

    PMID: 31189503
  22. 22

    Rare case of primary carnitine deficiency presenting as acute liver failure.

    Jain S, Kumar K, Malhotra S, Sibal A

    BMJ case reports 2022; (15(7)) doi:10.1136/bcr-2021-247225.

    PMID: 35853679
  23. 23

    Biochemical characteristics of newborns with carnitine transporter defect identified by newborn screening in California.

    Gallant NM, Leydiker K, Wilnai Y, et al.

    Molecular genetics and metabolism 2017; (122(3)):76-84 doi:10.1016/j.ymgme.2017.06.015.

    PMID: 28711408
  24. 24

    Harnessing Next-Generation Sequencing as a Timely and Accurate Second-Tier Screening Test for Newborn Screening of Inborn Errors of Metabolism.

    Chan TCH, Mak CM, Yeung MCW, et al.

    International journal of neonatal screening 2024; (10(1)) doi:10.3390/ijns10010019.

    PMID: 38535123

This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider or metabolic specialist regarding your specific SPCD diagnosis and treatment plan.

Stay up to date

Get notified when new research about Systemic primary carnitine deficiency is published.

No spam. Unsubscribe anytime.